PE20181921A1 - NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS - Google Patents
NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICASInfo
- Publication number
- PE20181921A1 PE20181921A1 PE2018001974A PE2018001974A PE20181921A1 PE 20181921 A1 PE20181921 A1 PE 20181921A1 PE 2018001974 A PE2018001974 A PE 2018001974A PE 2018001974 A PE2018001974 A PE 2018001974A PE 20181921 A1 PE20181921 A1 PE 20181921A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- new anti
- sirpa
- antibodies
- therapeutic applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a nuevos anticuerpos anti-SIRPa o un fragmento de union a antigeno del mismo que comprende: a) un dominio variable de cadena pesada que comprende HCDR1, HCDR2 y HCDR3 en la secuencia de aminoacidos SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 17 respectivamente y b) un dominio variable de cadena ligera que comprende LCDR1, LCDR2 y LCDR3 en la secuencia de aminoacidos SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 capaces de antagonizar especificamente la interaccion entre SIRPa y CD47, sin afectar la interaccion entre SIRPg Y CD47. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos anticuerpos son utiles en el tratamiento del cancer inflamatorio, cancer con celulas mieloides infiltradas, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| EP17305182 | 2017-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181921A1 true PE20181921A1 (es) | 2018-12-11 |
Family
ID=58185461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001974A PE20181921A1 (es) | 2016-04-14 | 2017-04-14 | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3443010B1 (es) |
| CN (1) | CN109071664B (es) |
| AU (1) | AU2017248626B2 (es) |
| BR (1) | BR112018070823A2 (es) |
| CA (1) | CA3020373A1 (es) |
| CO (1) | CO2018010855A2 (es) |
| EA (1) | EA201891882A1 (es) |
| PE (1) | PE20181921A1 (es) |
| PT (1) | PT3443010T (es) |
| SG (1) | SG11201808465UA (es) |
| WO (1) | WO2017178653A2 (es) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| MX2018012434A (es) | 2016-04-14 | 2019-06-06 | Ose Immunotherapeutics | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas. |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| BR112019016356A2 (pt) * | 2017-02-17 | 2020-04-07 | Ose Immunotherapeutics | anticorpo anti-sirpg humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação de antígeno, produto de combinação, método in vitro ou ex vivo, uso de pelo menos um anticorpo anti-sirpg de humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação ao antígeno, e, método in vitro de prever a resposta de um sujeito a um tratamento |
| WO2018190719A2 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| CA3058966A1 (en) | 2017-04-14 | 2018-10-18 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| LT3625259T (lt) * | 2017-05-16 | 2024-07-10 | Byondis B.V. | Anti-sirpalfa antikūnai |
| KR102646468B1 (ko) | 2017-08-02 | 2024-03-11 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd47 항체 및 이의 용도 |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| WO2019080883A1 (en) * | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| EA202091859A1 (ru) | 2018-03-13 | 2021-02-04 | Осе Иммьюнотерапьютикс | Применение антител к sirpa v1 человека и способ получения антител к sirpa v1 |
| CA3093838A1 (en) * | 2018-03-14 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Anti-polysialic acid antibodies and uses thereof |
| JP7393342B2 (ja) * | 2018-03-21 | 2023-12-06 | エーエルエックス オンコロジー インコーポレイテッド | シグナル調節タンパク質αに対する抗体及び使用方法 |
| SG11202011082UA (en) * | 2018-05-25 | 2020-12-30 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
| EP3822289A4 (en) | 2018-07-10 | 2022-04-13 | National University Corporation Kobe University | ANTI-SIRP-ALPHA ANTIBODIES |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| KR20210086619A (ko) * | 2018-09-27 | 2021-07-08 | 셀진 코포레이션 | SIRPα 결합 단백질 및 이의 사용 방법 |
| EP3873522A1 (en) | 2018-10-29 | 2021-09-08 | UMC Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| EP3880239A4 (en) * | 2018-11-14 | 2022-11-23 | Arch Oncology, Inc. | THERAPEUTIC SIRPalpha ANTIBODIES |
| CA3118966A1 (en) | 2018-11-15 | 2020-05-22 | Byondis B.V. | Humanized anti-sirpa antibodies |
| CN113574067A (zh) * | 2018-12-21 | 2021-10-29 | Ose免疫疗法公司 | 双功能抗PD-1/SIRPα分子 |
| US20220143210A1 (en) * | 2019-02-27 | 2022-05-12 | Fred Hutchinson Cancer Research Center | Hydrogel compositions and methods for treatement of malignancies |
| US20220235144A1 (en) * | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| EP3756688A1 (en) | 2019-06-25 | 2020-12-30 | Université de Nantes | Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection |
| JP2022545300A (ja) * | 2019-08-20 | 2022-10-27 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｓｉｒｐａ抗体 |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| MY209360A (en) | 2019-10-31 | 2025-07-03 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| MX2022006078A (es) | 2019-11-27 | 2022-08-02 | Alx Oncology Inc | Terapias de combinacion para el tratamiento del cancer. |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| CN111116713B (zh) * | 2020-01-07 | 2023-06-23 | 郑州大学 | Sirpa蛋白亲和环肽及其应用 |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| AU2021226023A1 (en) | 2020-02-28 | 2022-09-15 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| PH12022553153A1 (en) | 2020-05-19 | 2024-02-26 | Boehringer Ingelheim Int | Binding molecules for the treatment of cancer |
| CN115666620A (zh) | 2020-06-01 | 2023-01-31 | Alx肿瘤生物技术公司 | 用于治疗癌症的包含低甲基化剂的联合疗法 |
| CN116916919A (zh) | 2020-11-11 | 2023-10-20 | 第一三共株式会社 | 抗体-药物缀合物与抗SIRPα抗体的组合 |
| WO2022110922A1 (zh) | 2020-11-30 | 2022-06-02 | 启愈生物技术(上海)有限公司 | 抗SIRPα抗体或其抗原结合片段及应用 |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022247933A1 (zh) * | 2021-05-28 | 2022-12-01 | 百奥泰生物制药股份有限公司 | 抗SIPRα抗体及其应用 |
| CA3218692A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023013915A (es) | 2021-06-29 | 2024-01-25 | Seagen Inc | Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47. |
| EP4389767A4 (en) | 2021-08-17 | 2026-02-25 | Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd | Monoclonal antibodies targeting syrup? And their use |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| KR20240097895A (ko) | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CN118679183A (zh) | 2021-11-29 | 2024-09-20 | Ose免疫疗法公司 | 特异性拮抗剂抗sirpg抗体 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| CR20240386A (es) | 2022-03-17 | 2024-10-24 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CA3249472A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS |
| KR20250008738A (ko) | 2022-05-10 | 2025-01-15 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 항 SIRPα 항체의 조합 |
| JP2025523369A (ja) | 2022-06-01 | 2025-07-23 | エーエルエックス オンコロジー インコーポレイテッド | 尿路上皮癌腫を治療するための併用療法 |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN121358500A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞抑制分子的基于脂质的纳米粒及其用途 |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| EP4698533A1 (en) | 2023-04-21 | 2026-02-25 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN119192379B (zh) * | 2024-11-22 | 2025-01-28 | 四川省医学科学院·四川省人民医院 | 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| CN101970478A (zh) * | 2007-10-11 | 2011-02-09 | 大学健康网络 | 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物 |
| CN101780283A (zh) * | 2010-03-16 | 2010-07-21 | 中国人民解放军第二军医大学 | 信号调节蛋白α在制备预防和治疗肿瘤的DC疫苗中的应用 |
| CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
| SG11201607143UA (en) * | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
-
2017
- 2017-04-14 EA EA201891882A patent/EA201891882A1/ru unknown
- 2017-04-14 SG SG11201808465UA patent/SG11201808465UA/en unknown
- 2017-04-14 CA CA3020373A patent/CA3020373A1/en active Pending
- 2017-04-14 EP EP17718881.0A patent/EP3443010B1/en active Active
- 2017-04-14 CN CN201780023581.2A patent/CN109071664B/zh active Active
- 2017-04-14 BR BR112018070823-2A patent/BR112018070823A2/pt unknown
- 2017-04-14 PE PE2018001974A patent/PE20181921A1/es unknown
- 2017-04-14 WO PCT/EP2017/059071 patent/WO2017178653A2/en not_active Ceased
- 2017-04-14 PT PT177188810T patent/PT3443010T/pt unknown
- 2017-04-14 AU AU2017248626A patent/AU2017248626B2/en active Active
-
2018
- 2018-10-10 CO CONC2018/0010855A patent/CO2018010855A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018070823A2 (pt) | 2019-02-05 |
| AU2017248626A1 (en) | 2018-10-11 |
| EP3443010A2 (en) | 2019-02-20 |
| SG11201808465UA (en) | 2018-10-30 |
| AU2017248626B2 (en) | 2024-05-09 |
| CO2018010855A2 (es) | 2018-11-13 |
| CN109071664B (zh) | 2023-02-21 |
| EA201891882A1 (ru) | 2019-07-31 |
| EP3443010B1 (en) | 2024-08-07 |
| WO2017178653A2 (en) | 2017-10-19 |
| PT3443010T (pt) | 2024-10-21 |
| CA3020373A1 (en) | 2017-10-19 |
| WO2017178653A3 (en) | 2018-07-05 |
| CN109071664A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos |